Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Marvelbiome Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. The prosecution is distributed across 3 distinct art units.
Kimberly Catherine Breen is the busiest examiner for this portfolio, currently handling 2 pending office actions. This accounts for 2 of the 3 total pending actions. The involvement of 3 distinct art units for only 3 pending actions indicates that every single action falls under a different technical classification. Practitioners must navigate 3 distinct art units while working with only 2 distinct examiners. This suggests that Kimberly Catherine Breen is reviewing 2 pending office actions that are classified in different art units. The 3 pending office actions require a strategy that addresses the specific requirements of 3 distinct art units and the individual styles of 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 2 | 23.8% | +56.9% |
| REGLAS, GEORGIANA C | 1 | 37.7% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| 17765820 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | REGLAS, GEORGIANA C | 38d overdue |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| 17765820 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | BREEN, KIMBERLY CATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1651 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 1653 | §101§102§103§112DPOther | Non-Final OA | 75d | Pending | Mar 14, 2025 |
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | REGLAS, GEORGIANA C | 1651 | §112 | Final Rejection | 38d overdue | Pending | Dec 01, 2022 |
| 17765820 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | BREEN, KIMBERLY CATHERINE | 1657 | §103Other | Final Rejection | — | Pending | Mar 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial